共 68 条
[1]
van Duin D(2020)Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study Lancet Infect Dis 20 731-741
[2]
Arias CA(2022)Clinical outcomes and bacterial characteristics of carbapenem-resistant Lancet Infect Dis 22 401-412
[3]
Komarow L(2017) complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study Lancet Infect Dis 17 726-734
[4]
Wang M(2018)Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study Lancet Infect Dis 18 318-327
[5]
Earley M(2018)Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis Drugs 78 675-692
[6]
Chen L(2016)Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections Lancet Infect Dis 16 661-673
[7]
Gutierrez-Gutierrez B(2018)Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Lancet Infect Dis 18 285-295
[8]
Salamanca E(1994) complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study J Clin Epidemiol 47 1245-1251
[9]
de Cueto M(2017)Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial Ann Transl Med 5 7-740
[10]
Tacconelli E(2019)Validation of a combined comorbidity index Comput Biol Med 111 71-1713